West Pharma Corp (WST) - Long-Term Debt to Capital Ratio

Corporate emblem and logo of West Pharmaceutical Services (WST)

West Pharmaceutical Services produces injection components with stable demand that remains independent of seasonality or economic crises. Historical price action on the GURU.Markets platform, where the indicator is 0.10, links this resilience to the company's dominance in drug delivery systems. Due to strict sterility standards and complex certification, pharma behemoths are virtually unable to switch suppliers, creating an insurmountable barrier for competitors.

West Pharmaceutical Services Inc (WST) Long-Term Debt to Capital: for the period 07/04/2022 - 10/31/2026

Analytical breakdowns for West Pharmaceutical Services

- market price and analyst price targets:
Market Price West Pharma|WST - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization West Pharmaceutical Services, Inc.|WST - Enterprise Value
- issuer book value statistics:
Net Assets per Share West Pharmaceutical Services|WST - Book Capitalization|Market Cap to Net Assets Ratio westpharma.com|WST - Company Total Assets
- debt and solvency information:
Total Debt to Capital West Pharmaceutical Services|WST - Long-Term Debt to Equity|Short-Term Debt to Equity westpharma.com|WST - Company Total Debt|Debt to Net Assets Ratio West Pharmaceutical Services, Inc.|WST - Company Long-Term Debts|Short-Term Debt Volume West Pharmaceutical Services|Immediate Liquidity Ratio westpharma.com
- earnings and market multiples details:
WST - Company Net Income
General company analysis:West Pharma - WST
Core merchandise of westpharma.com

The stability of long-term contracts between West Pharmaceutical Services (WST) and pharmaceutical behemoths allows the company to effectively manage debt capital to scale production. This long-term debt-to-equity coverage ratio reflects the proportion of liabilities with a maturity of over one year relative to equity, where a declining curve minimizes default risk, while excessive conservatism may indicate an inefficient use of financial leverage.

Key competitors

Long-Term Liabilities to Capital Intuitive Surgical, Inc. ISRG|Long-Term Debt to Capital DHR|Becton Dickinson & Company - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital STE (STERIS plc)|Ratio of Long-Term Indebtedness to Capital baxter.com (BAX)|Masimo - Long-Term Debt to Capital|Stevanato Group SpA (STVN) - Long-Term Debt to Equity Ratio|TFX: Long-Term Debt to Capital|Merit Medical Corp (MMSI) - Long-Term Debt to Capital|Long-Term Debt to Equity Envista Holdings|Long-Term Debt to Equity ICUI|Long-Term Debt to Equity Ratio XRAY (Dentsply Sirona)|LMAT (LeMaitre Vascular Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ATRC (AtriCure Corp)|Ratio of Long-Term Indebtedness to Capital STAAR Surgical Co (STAA)|NAGE - Long-Term Debt to Equity|ZIMV (zimvie.com) - Long-Term Debt to Capital Ratio|AngioDynamics (ANGO) - Long-Term Debt to Equity|CERS - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio TKNO|MGRM (Monogram Orthopedics Inc.) - Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Sharps Technology, Inc. (STSS)|INFU (infusystem.com) - Long-Term Debt to Capital Coefficient|Utah Medical Products, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital KORU Medical Systems, Inc. KRMD|NYXH - Long-Term Debt to Equity|Microbot Medical, Inc (MBOT) - Long-Term Debt to Equity Ratio|PDEX: Long-Term Debt to Capital|Long-Term Liabilities to Capital zentek.com (ZTEK)|Long-Term Debt to Equity Elutia|Long-Term Debt to Capital Ratio MLSS (Milestone Scientific Inc)|Long-Term Debt to Equity Ratio NXGL (NEXGEL, Inc)|Long-Term Loans to Capital Ratio RVP|Long-Term Debt to Equity Harvard Bioscience, Inc. HBIO|Ratio of Long-Term Indebtedness to Capital femasys.com (FEMY)|MHUA: Long-Term Debt to Equity Ratio|Predictive Oncology (POAI) - Long-Term Debt to Equity Ratio|CJMB: Long-Term Debt to Capital|Long-Term Liabilities to Capital Atrion Corporation Inc. (ATRI)|Long-Term Debt to Equity NeuroMetrix, Inc.